PHOENIX, May 22, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announced that it has taken a significant step forward in the distribution of EvolveTM, the Company's minimum risk soft bait for the proactive control of rats, through the launch of a dedicated online store on Amazon, the world's largest online retailer. To purchase Evolve on Amazon, please visit this link. "Evolve isn't just a product; ...

SenesTech, Inc. (NASDAQ:SNES) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Operator Good day and welcome to the SenesTech Inc. Reports First Quarter Fiscal Year 2024 Financial Results Conference Call. All participants will be in a listen only mode. [Operator Instructions] After today's presentation, there will be an opp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) | Delaware | 20-2079805 | ...

Exhibit 99.1 SenesTech Announces First Quarter 2024 Financial Results PHOENIX, Ariz., May 9, 2024. SenesTech, Inc. (NASDAQ: SNES, “SenesTech” or the “Company”), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the first quarter of 2024. Recent Highlights • Record quarterly revenues during Q1 2024 of $415,000, an increase of 78% compared to Q1 2023. • Evolve™, ...

SenesTech, Inc. (NASDAQ:SNES) Q4 2023 Earnings Conference Call February 21, 2024 5:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Joel Fruendt - CEO Tom Chesterman - CFO Conference Call Participants Amit Dayal - H.C. Wainwright Operator Good afternoon, and welcome to the SenesTech Reports Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. I'd now like to turn the conference over to Robert Blum with Lytham ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR Indicate by check mark if the registr ...

Exhibit 99.1 SenesTech Announces 2023 Financial Results YTD 2024 total revenue up more than 80% compared to YTD 2023 driven by orders for Evolve soft bait TM PHOENIX, Ariz., February 21, 2024. SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2023 financial results. "During 2023, we executed on a number of key initiatives that will be the foundation t ...

SenesTech, Inc. (NASDAQ:SNES) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Joel Fruendt - Chief Executive Officer Tom Chesterman - Chief Financial Officer Conference Call Participants Operator Good afternoon. And welcome to the SenesTech Reports Third Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) | Delaware | 20-20798 ...

Forward-looking statements include, but are not limited to, our expectation regarding sales commitments, our expectation regarding the conversion of sales commitments and programs to revenue, our belief that our product is more humane, less harmful to the environment and more effective than traditional methods, and our belief that ContraPest will establish a new paradigm in rodent control without environmental effects of rodenticides. Rats cause over $27 billion in damage to public and private infrastructur ...